A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain.
José Ramón González JuanateyÁlvaro González FrancoPatricia de SequeraMarta VallsAntonio Ramirez de ArellanoElisenda PomaresDiana NievesPublished in: Journal of medical economics (2022)
Patiromer is a cost-effective intervention in maintaining normokalemia and enabling optimal RAASi therapy in patients with CKD stages 3-4 with and without HF in Spain.